Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer (GlobeNewswire) - Aug 22, 2024 - "Sutro Biopharma, Inc...today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025....Patients are expected to be dosed with 4.3 mg/kg of luvelta every three weeks."
P2 data • Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology
|